Clinical Trial Update: Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating imatinib mesylate in combination with gemcitabine for locally advanced, metastatic, or recurrent pancreatic cancer; the study has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Gleevec (Imatinib)

Snippet

Sponsor: Northwestern University | Conditions: Pancreatic Cancer | Phase 1 | Status: TERMINATED